 |
|
|
 |
NHLBI Researchers Find Long-Acting Beta-Agonists Not As Effective As Inhaled Corticosteroids In Treating Persistent Asthma
Researchers supported by the National Heart, Lung, and Blood Institute (NHLBI) yesterday reported findings from two studies that address an ongoing controversy about whether long-acting beta-agonists (LABs) should replace or supplement inhaled corticosteroids (ICS) in the treatment of adults with mild-to-moderate persistent asthma. more
|
|
Combination Treatment For Hepatitis C May Be More Effective Than Current Standard Of Care
New findings from a large international study led by researchers at the University of North Carolina at Chapel Hill suggest that a combination treatment with a new long-acting interferon drug and an antiviral medication may be more effective than the current standard of care for hepatitis C. more
|
|
|
|
FDA Approves New Device For Patients With Atrial Fibrillation
Providing new hope for a select group of often-hospitalized patients, the US Food and Drug Administration announced the approval of a new device-based therapy that improves quality of life and reduces the debilitating symptoms of atrial fibrillation. more
|
|
Side One: The New York Times Asks - Are Vioxx And Celebrex Safe For Your Patients?
The New York Times reported this morning that physicians are beginning to express concern that Vioxx and Celebrex, two very popular arthritis drugs, may not be as safe as they were initially believed to be. more
|
|
Side Two: The Companies Reply - Vioxx And Celebrex Are Safe
In response to news and analyst reports of data first released a year ago, Merck & Co., Inc. today reconfirmed the favorable cardiovascular safety profile of Vioxx. Celebrex manufacturers, Pharmacia and Pfizer Inc issued the following: The COX-2 specific inhibitors represent a major medical advance in the treatment of arthritis. Pharmacia and Pfizer maintain that molecular differences between the COX-2 specific inhibitors may account for the cardiovascular and renal safety differences seen between Celebrex (celecoxib capsules) and Vioxx. According to Pharmacia all clinical trials of Celebrex to date, representing over 30,000 patients and nearly two million patient-years of exposure, have shown no increased risk for heart attack and stroke. more
|
|
|
